Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

A New Mechanism for Primary Resistance to Gefitinib in Lung Adenocarcinoma: The Role of a Novel G796A Mutation in Exon 20 of EGFR

HIDETAKA URAMOTO, TAKESHI UCHIUMI, HIROTO IZUMI, KIMITOSHI KOHNO, TSUNEHIRO OYAMA, KENJI SUGIO and KOSEI YASUMOTO
Anticancer Research July 2007, 27 (4B) 2297-2303;
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI UCHIUMI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTO IZUMI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIMITOSHI KOHNO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUNEHIRO OYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI SUGIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kensugio@med.uoeh-u.ac.jp
KOSEI YASUMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

  • EGFR
  • TKI
  • gefitinib
  • mutation
  • lung cancer
  • resistance

Footnotes

  • Received January 19, 2007.
  • Revision received March 22, 2007.
  • Accepted March 27, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (4B)
Anticancer Research
Vol. 27, Issue 4B
July-August 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A New Mechanism for Primary Resistance to Gefitinib in Lung Adenocarcinoma: The Role of a Novel G796A Mutation in Exon 20 of EGFR
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
A New Mechanism for Primary Resistance to Gefitinib in Lung Adenocarcinoma: The Role of a Novel G796A Mutation in Exon 20 of EGFR
HIDETAKA URAMOTO, TAKESHI UCHIUMI, HIROTO IZUMI, KIMITOSHI KOHNO, TSUNEHIRO OYAMA, KENJI SUGIO, KOSEI YASUMOTO
Anticancer Research Jul 2007, 27 (4B) 2297-2303;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
A New Mechanism for Primary Resistance to Gefitinib in Lung Adenocarcinoma: The Role of a Novel G796A Mutation in Exon 20 of EGFR
HIDETAKA URAMOTO, TAKESHI UCHIUMI, HIROTO IZUMI, KIMITOSHI KOHNO, TSUNEHIRO OYAMA, KENJI SUGIO, KOSEI YASUMOTO
Anticancer Research Jul 2007, 27 (4B) 2297-2303;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer
  • EGFR-Activating Mutations Are Not Present in Breast Tumors of Japanese Patients
  • Google Scholar

More in this TOC Section

  • Role of Platelet Interactions in Promoting Melanoma Malignancy With Insights into Proliferation, Cyclin D1 Expression, and Migration
  • Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts
  • Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep Learning Approaches and Graphical Data Transformation
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire